PTC Therapeutics EV/EBIT PTCT

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2025.

Today, Oct 23, 2026: 27.2×
Peer median: 56.1×

PTC Therapeutics' EV/EBIT is 27.2× as of Oct 23, 2026.

The median for 10 large drugmakers of a similar size is 56.1×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	27.2×	4.6×	35.7×
2025	5.4×	2.0×	6.0×

Against its peers

Companies in Drug Manufacturers - General nearest PTC Therapeutics' size, closest first, today.

Company	EV/EBIT
PTCTPTC Therapeutics	27.2×
KNSAKiniksa Pharmaceuticals International	54.6×
LGNDLigand Pharmaceuticals	57.7×
INDVIndivior Pharmaceuticals	7.8×
AMRXAmneal Pharmaceuticals	18.3×
ARQTArcutis Biotherapeutics	111×
LQDALiquidia	21.7×
OGNOrganon	9.5×
ALKSAlkermes plc.	69.6×
TGTXTG Therapeutics	62.2×
PTGXProtagonist Therapeutics	140×
Peer median	56.1×

Where PTC Therapeutics ranks

#38of 48Large drugmakers with the lowest EV/EBIT

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on PTC Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.